HCC

Martin E. Gutierrez, MD, director, Drug Discovery/Phase I Unit, and co-chief and medical oncologist, Divisions of Thoracic Oncology and Gastrointestinal Oncology, John Theurer Cancer Center, Hackensack University Medical Center, discusses the early findings for H3B-6527, an FGFR4 inhibitor, as a treatment of patients with hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma

General Cancer

Catherine Frenette, MD, explained in a Targeted Oncology live case-based peer perspectives presentation how she treats patients with hepatocellular carcinoma across the course of disease.

Aiwu Ruth He, MD, PhD, discusses treatment options in a&nbsp;<em>Targeted Oncology </em>live case-based peer perspectives discussion&nbsp;based on 2 case studies of patients with hepatocellular carcinoma.&nbsp;

Significant activity was observed when ibrutinib was administered concurrently with CD19-directed CAR T-cell therapy compared with separately in patients with&nbsp;high-risk relapsed/refractory chronic lymphocytic leukemia who had progressed on or were intolerant of ibrutinib.&nbsp;Data presented at the 15th International Conference on Malignant Lymphoma show a high response rate with this concurrent treatment.&nbsp;

Topline results from the&nbsp;phase III CheckMate 459 trial revealed that the trial did not meet its primary endpoint of improved overall survival with nivolumab as compared with sorafenib for the treatment of patients with newly diagnosed, unresectable hepatocellular carcinoma.&nbsp;

The American Cancer Society, Dana-Farber Cancer Institute, Baptist Cancer Center, and the Mayo Clinic report&nbsp;that treatment patterns varied markedly by cancer type and care facility setting for patients with de novo metastatic disease who died within 1 month after diagnosis, based on an analysis of data from 100,848 patients collected from the National Cancer Database, a hospital-based cancer registry that captures 70% of patients in the United States with a new diagnosis.

The FDA recently released 5 new draft guidance documents that promote broader patient eligibility for cancer clinical trials. The policies encourage inclusion of certain individuals who were previously disqualified due to medical conditions or biological factors, including brain metastases, organ dysfunction, prior or concurrent malignancies, chronic infections, and age.

A cohort of cancer centers was selected to serve as models for identifying key strategies for racial and ethnic minority group engagement in clinical trials. On the basis of several qualifying criteria, such as sustained accrual of minorities into clinical cancer research, an established minority population &ge;10% in the overall catchment, an established clinical trial infrastructure, and a formal community outreach program, the investigators identified 8 cancer centers for participation.

Josep M. Llovet, MD, PhD, discusses the evolution of treatment options for patients with hepatocellular carcinoma.

In a case-based-style discussion, Tanios S. Bekaii-Saab, MD, and Wells Messersmith, MD, reviewed the treatment of patients with colorectal cancer whose tumors express rare gene mutations or molecular signatures, such as <em>NTRK</em> fusions.

In an interview with&nbsp;<em>Targeted Oncology,&nbsp;</em>Andrew X. Zhu, MD, PhD, FACP, discussed the results from the REACH-2 trial and the significance of the approval of ramucirumab monotherapy in patients with advanced HCC and high AFP levels who have previously failed sorafenib.